VCC-1 Activators are a diverse group of chemical compounds that indirectly promote the functional activity of VCC-1, primarily through modulating receptor interactions and immune cell functions. Compounds like SB225002, Reparixin, and SCH527123, which are CXCR2 antagonists, play a pivotal role in enhancing VCC-1 activity. By reducing competitive binding at CXCR2, these compounds increase the availability of CXCL17 receptors, which are crucial for VCC-1 binding and subsequent activation. This mechanism is especially significant in facilitating VCC-1 mediated chemotactic signaling, which is central to its role in immune modulation. Furthermore, macrolide antibiotics such as Azithromycin and Clarithromycin, known for their anti-inflammatory properties, can indirectly augment VCC-1 activity. They achieve this by modulating macrophage functions, which in turn could increase CXCL17 receptor expression, thus enhancing the potential for VCC-1 interaction and activity.
Additionally, PPAR-gamma agonists like Rosiglitazone and Pioglitazone contribute to the enhancement of VCC-1 activity. They exert their effects by influencing macrophage polarization, a process that can affect the dynamics of CXCL17 receptors relevant for VCC-1 interaction. This modulation of macrophage function is crucial for optimizing the immunomodulatory effects of VCC-1. Natural compounds such as Curcumin, Resveratrol, and Sulforaphane, known for their anti-inflammatory properties, further support VCC-1 activity. These compounds modulate immune cell functions, potentially affecting the availability of CXCL17 receptors for effective VCC-1 engagement. Vitamin D3, through its immunomodulatory effects, also plays a role in enhancing VCC-1 activity by influencing macrophage function and, consequently, CXCL17 receptor expression. Omega-3 Fatty Acids, particularly EPA and DHA, augment VCC-1 activity through their anti-inflammatory effects, which can influence CXCL17 receptor dynamics, facilitating effective VCC-1 interaction. Together, these VCC-1 Activators, through their targeted effects on receptor interactions and immune cell modulation, facilitate the enhancement of VCC-1 mediated functions, crucial for orchestrating effective immune responses.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 225002 | 182498-32-4 | sc-202803 sc-202803A | 1 mg 5 mg | $36.00 $102.00 | 2 | |
SB225002, a CXCR2 antagonist, indirectly enhances VCC-1 activity by reducing competitive binding at CXCR2, potentially increasing the availability of CXCL17 receptors for VCC-1 binding and activation. | ||||||
Lonafarnib | 193275-84-2 | sc-482730 sc-482730A | 5 mg 10 mg | $173.00 $234.00 | ||
Reparixin, another CXCR2 inhibitor, can indirectly augment VCC-1 activity by minimizing competition at the receptor, facilitating VCC-1 mediated chemotactic signaling. | ||||||
Azithromycin | 83905-01-5 | sc-254949 sc-254949A sc-254949B sc-254949C sc-254949D | 25 mg 50 mg 500 mg 1 g 5 g | $52.00 $103.00 $260.00 $364.00 $728.00 | 17 | |
Azithromycin, known for its anti-inflammatory properties, may indirectly enhance VCC-1 activity by modulating macrophage functions, which could increase CXCL17 receptor availability for VCC-1. | ||||||
Clarithromycin | 81103-11-9 | sc-205634 sc-205634A | 100 mg 250 mg | $77.00 $122.00 | 1 | |
Clarithromycin, similar to Azithromycin, could indirectly enhance VCC-1 activity by affecting macrophage activity, possibly leading to increased CXCL17 receptor expression for VCC-1 interaction. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
Rosiglitazone, a PPAR-gamma agonist, may indirectly increase VCC-1 activity by modulating macrophage polarization, which can affect CXCL17 receptor dynamics relevant for VCC-1. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $55.00 $125.00 | 13 | |
Pioglitazone, another PPAR-gamma agonist, potentially enhances VCC-1 activity indirectly by influencing macrophage polarization and CXCL17 receptor expression. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin, with its anti-inflammatory properties, may indirectly enhance VCC-1 activity by modulating immune cell function, potentially affecting CXCL17 receptor availability for VCC-1. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol, known for its anti-inflammatory effects, could indirectly enhance VCC-1 activity by modulating immune responses, which may influence CXCL17 receptor dynamics for VCC-1. | ||||||
Cholecalciferol | 67-97-0 | sc-205630 sc-205630A sc-205630B | 1 g 5 g 10 g | $71.00 $163.00 $296.00 | 2 | |
Vitamin D3, through its immunomodulatory effects, may indirectly enhance VCC-1 activity by influencing macrophage function and CXCL17 receptor expression relevant to VCC-1. | ||||||
D,L-Sulforaphane | 4478-93-7 | sc-207495A sc-207495B sc-207495C sc-207495 sc-207495E sc-207495D | 5 mg 10 mg 25 mg 1 g 10 g 250 mg | $153.00 $292.00 $489.00 $1325.00 $8465.00 $933.00 | 22 | |
Sulforaphane, with its impact on inflammatory pathways, could indirectly enhance VCC-1 activity by modulating immune cell functions, potentially affecting CXCL17 receptor availability for VCC-1. | ||||||